IFNG and neoplasm: Alternative mechanism by which IFN-γ contributes to efficiency of cancer immunotherapy was described by Wang et al. In that model, tumor-infiltrating CD8+ T-cells secreted IFN-γ in response to nivolumab, an anti-PD-L1 antibody.